Availability of Medications for the Treatment of Alcohol and Opioid Use Disorder in the USA

Despite high mortality rates due to opioid overdose and excessive alcohol consumption, medications for the treatment of alcohol and opioid use disorder have not been widely used in the USA. This paper provides an overview of the literature on the availability of alcohol and opioid used disorder medi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Neurotherapeutics 2020, Vol.17 (1), p.55-69
Hauptverfasser: Abraham, Amanda J., Andrews, Christina M., Harris, Samantha J., Friedmann, Peter D.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 69
container_issue 1
container_start_page 55
container_title Neurotherapeutics
container_volume 17
creator Abraham, Amanda J.
Andrews, Christina M.
Harris, Samantha J.
Friedmann, Peter D.
description Despite high mortality rates due to opioid overdose and excessive alcohol consumption, medications for the treatment of alcohol and opioid use disorder have not been widely used in the USA. This paper provides an overview of the literature on the availability of alcohol and opioid used disorder medications in the specialty substance use disorder treatment system, other treatment settings and systems, and among providers with a federal waiver to prescribe buprenorphine. We also present the most current data on the availability of alcohol and opioid use disorder medications in the USA. These estimates show steady growth in availability of opioid use disorder medications over the past decade and a decline in availability of alcohol use disorder medications. However, overall use of medications in the USA remains low. In 2017, only 16.3% of specialty treatment programs offered any single medication for alcohol use disorder treatment and 35.5% offered any single medication for opioid use disorder treatment. Availability of buprenorphine-waivered providers has increased significantly since 2002. However, geographic disparities in access to buprenorphine remain. Some of the most promising strategies to increase availability of alcohol and opioid use disorder medications include the following: incorporating substance use disorder training in healthcare education programs, educating the substance use disorder workforce about the benefits of medication treatment, reducing stigma surrounding the use of medications, implementing medications in primary care settings, implementing integrated care models, revising regulations on methadone and buprenorphine, improving health insurance coverage of medications, and developing novel medications for the treatment of substance use disorder.
doi_str_mv 10.1007/s13311-019-00814-4
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7007488</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2788020071</sourcerecordid><originalsourceid>FETCH-LOGICAL-c474t-319e949206c84f92a43af47ef0c4b643fdf25032993ca5eae3ab64a844c815fd3</originalsourceid><addsrcrecordid>eNp1UU1PAyEUJEZja_UPeDAknldhYQtcTJr6mdT0YHvyQCgLLc12qbBt0n8v_bDRg-_Cy3sz8yYMANcY3WGE2H3EhGCcISwyhDimGT0BbcwZzxhl4jT1gpCM5Zi0wEWMc4QKQgQ_By2CBWKcddvgs7dWrlITV7lmA72F76Z0WjXO1xFaH2AzM3AUjGoWpm62gF6l_cxXUNUlHC6ddyUcRwMfXfShNAG6escZf_QuwZlVVTRXh7cDxs9Po_5rNhi-vPV7g0xTRpssmTGCihx1NadW5IoSZSkzFmk66VJiS5sXiORCEK0KowxRaaw4pZrjwpakAx72usvVZGFKnYwGVcllcAsVNtIrJ_9uajeTU7-WLP0i5TwJ3B4Egv9amdjIuV-FOnmWOBXjHBXdhMr3KB18jMHY4wWM5DYQuQ9EpkDkLhBJE-nmt7cj5SeBBCB7QEyremrCr9v_y34DZF6WmA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1111788056</pqid></control><display><type>article</type><title>Availability of Medications for the Treatment of Alcohol and Opioid Use Disorder in the USA</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><source>SpringerLink Journals - AutoHoldings</source><creator>Abraham, Amanda J. ; Andrews, Christina M. ; Harris, Samantha J. ; Friedmann, Peter D.</creator><creatorcontrib>Abraham, Amanda J. ; Andrews, Christina M. ; Harris, Samantha J. ; Friedmann, Peter D.</creatorcontrib><description>Despite high mortality rates due to opioid overdose and excessive alcohol consumption, medications for the treatment of alcohol and opioid use disorder have not been widely used in the USA. This paper provides an overview of the literature on the availability of alcohol and opioid used disorder medications in the specialty substance use disorder treatment system, other treatment settings and systems, and among providers with a federal waiver to prescribe buprenorphine. We also present the most current data on the availability of alcohol and opioid use disorder medications in the USA. These estimates show steady growth in availability of opioid use disorder medications over the past decade and a decline in availability of alcohol use disorder medications. However, overall use of medications in the USA remains low. In 2017, only 16.3% of specialty treatment programs offered any single medication for alcohol use disorder treatment and 35.5% offered any single medication for opioid use disorder treatment. Availability of buprenorphine-waivered providers has increased significantly since 2002. However, geographic disparities in access to buprenorphine remain. Some of the most promising strategies to increase availability of alcohol and opioid use disorder medications include the following: incorporating substance use disorder training in healthcare education programs, educating the substance use disorder workforce about the benefits of medication treatment, reducing stigma surrounding the use of medications, implementing medications in primary care settings, implementing integrated care models, revising regulations on methadone and buprenorphine, improving health insurance coverage of medications, and developing novel medications for the treatment of substance use disorder.</description><identifier>ISSN: 1933-7213</identifier><identifier>ISSN: 1878-7479</identifier><identifier>EISSN: 1878-7479</identifier><identifier>DOI: 10.1007/s13311-019-00814-4</identifier><identifier>PMID: 31907876</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>Alcohol use ; Alcoholism - drug therapy ; Biomedical and Life Sciences ; Biomedicine ; Buprenorphine ; Drug use ; Health Services Accessibility - statistics &amp; numerical data ; Humans ; Methadone ; Narcotics ; Neurobiology ; Neurology ; Neurosciences ; Neurosurgery ; Opioid-Related Disorders - drug therapy ; Opioids ; Overdose ; Review ; United States</subject><ispartof>Neurotherapeutics, 2020, Vol.17 (1), p.55-69</ispartof><rights>The American Society for Experimental NeuroTherapeutics, Inc. 2020</rights><rights>Neurotherapeutics is a copyright of Springer, (2020). All Rights Reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c474t-319e949206c84f92a43af47ef0c4b643fdf25032993ca5eae3ab64a844c815fd3</citedby><cites>FETCH-LOGICAL-c474t-319e949206c84f92a43af47ef0c4b643fdf25032993ca5eae3ab64a844c815fd3</cites><orcidid>0000-0002-7455-7464</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7007488/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7007488/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,315,728,781,785,886,27926,27927,41490,42559,51321,53793,53795</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31907876$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Abraham, Amanda J.</creatorcontrib><creatorcontrib>Andrews, Christina M.</creatorcontrib><creatorcontrib>Harris, Samantha J.</creatorcontrib><creatorcontrib>Friedmann, Peter D.</creatorcontrib><title>Availability of Medications for the Treatment of Alcohol and Opioid Use Disorder in the USA</title><title>Neurotherapeutics</title><addtitle>Neurotherapeutics</addtitle><addtitle>Neurotherapeutics</addtitle><description>Despite high mortality rates due to opioid overdose and excessive alcohol consumption, medications for the treatment of alcohol and opioid use disorder have not been widely used in the USA. This paper provides an overview of the literature on the availability of alcohol and opioid used disorder medications in the specialty substance use disorder treatment system, other treatment settings and systems, and among providers with a federal waiver to prescribe buprenorphine. We also present the most current data on the availability of alcohol and opioid use disorder medications in the USA. These estimates show steady growth in availability of opioid use disorder medications over the past decade and a decline in availability of alcohol use disorder medications. However, overall use of medications in the USA remains low. In 2017, only 16.3% of specialty treatment programs offered any single medication for alcohol use disorder treatment and 35.5% offered any single medication for opioid use disorder treatment. Availability of buprenorphine-waivered providers has increased significantly since 2002. However, geographic disparities in access to buprenorphine remain. Some of the most promising strategies to increase availability of alcohol and opioid use disorder medications include the following: incorporating substance use disorder training in healthcare education programs, educating the substance use disorder workforce about the benefits of medication treatment, reducing stigma surrounding the use of medications, implementing medications in primary care settings, implementing integrated care models, revising regulations on methadone and buprenorphine, improving health insurance coverage of medications, and developing novel medications for the treatment of substance use disorder.</description><subject>Alcohol use</subject><subject>Alcoholism - drug therapy</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Buprenorphine</subject><subject>Drug use</subject><subject>Health Services Accessibility - statistics &amp; numerical data</subject><subject>Humans</subject><subject>Methadone</subject><subject>Narcotics</subject><subject>Neurobiology</subject><subject>Neurology</subject><subject>Neurosciences</subject><subject>Neurosurgery</subject><subject>Opioid-Related Disorders - drug therapy</subject><subject>Opioids</subject><subject>Overdose</subject><subject>Review</subject><subject>United States</subject><issn>1933-7213</issn><issn>1878-7479</issn><issn>1878-7479</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp1UU1PAyEUJEZja_UPeDAknldhYQtcTJr6mdT0YHvyQCgLLc12qbBt0n8v_bDRg-_Cy3sz8yYMANcY3WGE2H3EhGCcISwyhDimGT0BbcwZzxhl4jT1gpCM5Zi0wEWMc4QKQgQ_By2CBWKcddvgs7dWrlITV7lmA72F76Z0WjXO1xFaH2AzM3AUjGoWpm62gF6l_cxXUNUlHC6ddyUcRwMfXfShNAG6escZf_QuwZlVVTRXh7cDxs9Po_5rNhi-vPV7g0xTRpssmTGCihx1NadW5IoSZSkzFmk66VJiS5sXiORCEK0KowxRaaw4pZrjwpakAx72usvVZGFKnYwGVcllcAsVNtIrJ_9uajeTU7-WLP0i5TwJ3B4Egv9amdjIuV-FOnmWOBXjHBXdhMr3KB18jMHY4wWM5DYQuQ9EpkDkLhBJE-nmt7cj5SeBBCB7QEyremrCr9v_y34DZF6WmA</recordid><startdate>2020</startdate><enddate>2020</enddate><creator>Abraham, Amanda J.</creator><creator>Andrews, Christina M.</creator><creator>Harris, Samantha J.</creator><creator>Friedmann, Peter D.</creator><general>Springer International Publishing</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88G</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>M2M</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-7455-7464</orcidid></search><sort><creationdate>2020</creationdate><title>Availability of Medications for the Treatment of Alcohol and Opioid Use Disorder in the USA</title><author>Abraham, Amanda J. ; Andrews, Christina M. ; Harris, Samantha J. ; Friedmann, Peter D.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c474t-319e949206c84f92a43af47ef0c4b643fdf25032993ca5eae3ab64a844c815fd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Alcohol use</topic><topic>Alcoholism - drug therapy</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Buprenorphine</topic><topic>Drug use</topic><topic>Health Services Accessibility - statistics &amp; numerical data</topic><topic>Humans</topic><topic>Methadone</topic><topic>Narcotics</topic><topic>Neurobiology</topic><topic>Neurology</topic><topic>Neurosciences</topic><topic>Neurosurgery</topic><topic>Opioid-Related Disorders - drug therapy</topic><topic>Opioids</topic><topic>Overdose</topic><topic>Review</topic><topic>United States</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Abraham, Amanda J.</creatorcontrib><creatorcontrib>Andrews, Christina M.</creatorcontrib><creatorcontrib>Harris, Samantha J.</creatorcontrib><creatorcontrib>Friedmann, Peter D.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Psychology Database</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Neurotherapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Abraham, Amanda J.</au><au>Andrews, Christina M.</au><au>Harris, Samantha J.</au><au>Friedmann, Peter D.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Availability of Medications for the Treatment of Alcohol and Opioid Use Disorder in the USA</atitle><jtitle>Neurotherapeutics</jtitle><stitle>Neurotherapeutics</stitle><addtitle>Neurotherapeutics</addtitle><date>2020</date><risdate>2020</risdate><volume>17</volume><issue>1</issue><spage>55</spage><epage>69</epage><pages>55-69</pages><issn>1933-7213</issn><issn>1878-7479</issn><eissn>1878-7479</eissn><abstract>Despite high mortality rates due to opioid overdose and excessive alcohol consumption, medications for the treatment of alcohol and opioid use disorder have not been widely used in the USA. This paper provides an overview of the literature on the availability of alcohol and opioid used disorder medications in the specialty substance use disorder treatment system, other treatment settings and systems, and among providers with a federal waiver to prescribe buprenorphine. We also present the most current data on the availability of alcohol and opioid use disorder medications in the USA. These estimates show steady growth in availability of opioid use disorder medications over the past decade and a decline in availability of alcohol use disorder medications. However, overall use of medications in the USA remains low. In 2017, only 16.3% of specialty treatment programs offered any single medication for alcohol use disorder treatment and 35.5% offered any single medication for opioid use disorder treatment. Availability of buprenorphine-waivered providers has increased significantly since 2002. However, geographic disparities in access to buprenorphine remain. Some of the most promising strategies to increase availability of alcohol and opioid use disorder medications include the following: incorporating substance use disorder training in healthcare education programs, educating the substance use disorder workforce about the benefits of medication treatment, reducing stigma surrounding the use of medications, implementing medications in primary care settings, implementing integrated care models, revising regulations on methadone and buprenorphine, improving health insurance coverage of medications, and developing novel medications for the treatment of substance use disorder.</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><pmid>31907876</pmid><doi>10.1007/s13311-019-00814-4</doi><tpages>15</tpages><orcidid>https://orcid.org/0000-0002-7455-7464</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1933-7213
ispartof Neurotherapeutics, 2020, Vol.17 (1), p.55-69
issn 1933-7213
1878-7479
1878-7479
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7007488
source MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Alma/SFX Local Collection; SpringerLink Journals - AutoHoldings
subjects Alcohol use
Alcoholism - drug therapy
Biomedical and Life Sciences
Biomedicine
Buprenorphine
Drug use
Health Services Accessibility - statistics & numerical data
Humans
Methadone
Narcotics
Neurobiology
Neurology
Neurosciences
Neurosurgery
Opioid-Related Disorders - drug therapy
Opioids
Overdose
Review
United States
title Availability of Medications for the Treatment of Alcohol and Opioid Use Disorder in the USA
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-18T11%3A25%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Availability%20of%20Medications%20for%20the%20Treatment%20of%20Alcohol%20and%20Opioid%20Use%20Disorder%20in%20the%20USA&rft.jtitle=Neurotherapeutics&rft.au=Abraham,%20Amanda%20J.&rft.date=2020&rft.volume=17&rft.issue=1&rft.spage=55&rft.epage=69&rft.pages=55-69&rft.issn=1933-7213&rft.eissn=1878-7479&rft_id=info:doi/10.1007/s13311-019-00814-4&rft_dat=%3Cproquest_pubme%3E2788020071%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1111788056&rft_id=info:pmid/31907876&rfr_iscdi=true